Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Total Liabilities (2018 - 2025)

BioNexus Gene Lab's Total Liabilities history spans 8 years, with the latest figure at $804966.0 for Q3 2025.

  • For Q3 2025, Total Liabilities fell 49.91% year-over-year to $804966.0; the TTM value through Sep 2025 reached $804966.0, down 49.91%, while the annual FY2024 figure was $2.1 million, 21.19% up from the prior year.
  • Total Liabilities for Q3 2025 was $804966.0 at BioNexus Gene Lab, down from $1.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $3.1 million in Q1 2021 and bottomed at $804966.0 in Q3 2025.
  • The 5-year median for Total Liabilities is $1.8 million (2024), against an average of $1.9 million.
  • The largest annual shift saw Total Liabilities soared 3224.06% in 2021 before it tumbled 49.91% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $2.4 million in 2021, then fell by 13.34% to $2.1 million in 2022, then dropped by 16.06% to $1.7 million in 2023, then increased by 21.19% to $2.1 million in 2024, then plummeted by 61.87% to $804966.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Total Liabilities are $804966.0 (Q3 2025), $1.9 million (Q2 2025), and $1.7 million (Q1 2025).